The EU Biotech Act Is Coming – Will Your Business Be Ready?

The European Commission has published its long‑awaited Biotech Act (COM/2025/1022). It promises faster approvals, more clinical trials, and AI‑driven innovation. But beneath the headlines lie specific articles that could increase your compliance burden, expose you to new liability, and create competitive disadvantages – especially if you are an SME or a non‑EU company.

This article gives you verifiable facts from the actual legislative text.

You will learn:

• The real permit timelines for “strategic projects” – and the loophole that can add 3 months.
• How mandatory biosecurity reporting (24 hours, 3‑year records) affects your daily operations.
• Why the clinical trial reforms may still favour large pharma over smaller innovators.
• What Phase 2 (industrial biotech) means for chemical, material, and bio‑manufacturing firms – coming in 2026.
• The single most contested article in trilogues (Article 12 – permit‑granting deadlines).

If your business depends on speed to market, confidential customer data, or flexible R&D, read on. Then contact us to influence the final text before it becomes binding.

1. What the Biotech Act Actually Does – Four Concrete Changes

Key takeaway: Faster on paper – but new compliance layers could erase the gains, especially for SMEs.

Funding: One of the most crucial questions is how not to lose European BioTech projects to the US. To help resolve this, the proposal indicates that within the European Competitiveness Fund, strategic BioTech projects would receive a total allocation of EUR 20.4 billion for the period 2028–2034. While it is not at the same level as American venture capital, it is a valiant attempt to keep innovations within the EU.

2. The Hidden Risks – What the Commission Doesn’t Emphasise

Most briefings focus on the opportunities. Here is what your legal and public affairs team needs to worry about – all mentioned with the verifiable article number from the proposal text.

Risk 1 – The Permit Loophole (Article 12(6))

The headline is 10 months (or 8 for high‑impact). But the text allows an extension of “up to three additional months” where “duly justified cases” exist – for example, “complex procedures under Union or national legislation”. That loophole could become standard practice. Your competitor in the US may get a 6‑month review while you wait 13 months.

Risk 2 – 24‑Hour Biosecurity Reporting (Article 46(4))

If you sell or transfer any “biotechnology product of concern” (Annex I – includes synthetic DNA sequences and benchtop synthesisers), you must report any suspicious transaction within 24 hours to a national contact point. Failure to identify a suspicious transaction could lead to fines up to 5% of annual worldwide turnover (Article 51(2), page 112). For a small gene synthesis company, that is existential.

Risk 3 – Three‑Year Record Retention (Article 44(6))

Even if a transaction is legitimate, you must keep records for three years and make them available “without undue delay” upon request. That means storing customer identity, order details, and intended use – creating GDPR and trade secret exposure.

Risk 4 – Clinical Trial Reforms May Not Help SMEs

The CTR amendments (Article 58) shorten timelines, but they also introduce a new “investigational medicinal product core dossier” (Article 27a, page 147) and more reliance on a “reporting Member State”. Large pharma with dedicated regulatory teams will benefit most. Small biotechs may struggle to navigate the new complexity.

Risk 5 – Phase 2 (BioTech Act II on Industrial Biotech) Uncertainty

The proposal explicitly states (recital after page 6): “In a second stage, following this health‑focused initiative, the Commission will address in 2026 the wider biotech ecosystem beyond health.” If you manufacture bio‑based plastics, industrial enzymes, or bio‑chemicals, you have zero certainty on rules for open environments, waste streams, or cross‑border manufacturing. Waiting until end 2026 is a strategy of failure.

Risk 6 – Biosecurity Applies to Non‑EU Providers (Article 44(7))

The obligations apply to “any natural or legal person” making products available “on the Union market or to any natural or legal person outside the Union”. Non‑EU suppliers serving European customers must comply – or be cut off. If you source synthetic DNA from a US provider, they will need to screen your orders and report suspicions to an EU contact point. That adds friction and potential supply chain disruption.

3. The Political Battleground – Where the Fight Will Happen

Understanding the politics helps you predict amendments.

• Most contested article: Article 12 (permit‑granting timeline). Greens and S&D will push to remove or tightly limit the “duly justified” extension. Industry (EPP, Renew) will fight for automatic approval if deadlines are missed.
• Second most contested: Article 46 (24‑hour reporting). SMEs and trade associations will argue the timeframe is unrealistic. Expect attempts to extend to 5‑7 days.
• Parliament fault lines: EPP and Renew support faster permits and lighter biosecurity. Greens and S&D demand stronger oversight, public interest conditions, and stricter environmental assessments for strategic projects.
• Council configuration: Competitiveness Council leads, but EPSCO (health ministers) will weigh in on clinical trial changes.

Unexpected flashpoint: Article 33 (data quality accelerators). The proposal mentions the European Health Data Space (EHDS) but does not impose binding data quality obligations. Some Member States (Germany, France) may try to introduce stricter rules during trilogues, creating uncertainty for AI‑driven biotech.

4. What Analysts Are Getting Wrong

Most commentators celebrate the “pro‑innovation shift”. But they miss:

• Biosecurity as a non‑tariff barrier. The 24‑hour reporting and three‑year records will disproportionately hit small and non‑EU providers. Large incumbents with dedicated compliance teams will adapt easily – consolidating market power.
• Permit extensions swallow the rule. If every “complex” project claims a three‑month extension, the 10‑month target becomes 13 months. The text lacks an independent check on what counts as “duly justified”.
• Phase 2 – BioTech Act II – is a ghost. The industrial biotech provisions do not exist yet. Any company planning investments in bio‑based manufacturing is flying blind until end 2026/or mid-2027.

5. Why You Need a Public Affairs Strategy Now

The Biotech Act is in the ordinary legislative procedure (co‑decision). The Commission has published its proposal; the European Parliament and Council will now amend it. Your window to influence:

• Q2 2026: Parliamentary committees (SANT, ITRE) appointed rapporteurs (Vytenis Povilas ANDRIUKAITIS (S-D), Wouter BEKE (EPP)) and shadow rapporteurs. Amendments are being drafted.
• Q2 2026: Council working group discussions (Employment, Social Policy, Health and Consumer Affairs Council, and Working Party on Pharmaceuticals and Medical Devices) – as Member States form positions.
• Q3-Q4 2026: Trilogues. By then, the text is largely locked.

If you wait until the final text, you lose. Every article that harms your business – from the permit loophole to biosecurity reporting – can still be changed. But only if you have a targeted advocacy plan that speaks to the right MEPs, Council attachés, and Commission officials.

6. How I Can Help You Influence the Biotech Act

I am a Brussels‑based public affairs consultant working on files including EU health and industrial policy. I do not write generic position papers. I build evidence‑based influencing strategies that:

• Identify which amendments to file (and with which MEPs).
• Quantify the economic impact of specific articles (e.g., cost of 24‑hour reporting vs. 5‑day reporting).
• Mobilise coalitions with like‑minded stakeholders (trade associations, research institutions, patient groups).
• Prepare one‑pagers, testimonies, and technical briefings that officials actually read.
• Monitor Council working group positions in real time so you are never surprised.

Your Business Is at Risk – Let’s Talk

Do not wait for the trilogues. By then, the political compromises are done.

Use the contact form below to contact me for a confidential 30‑minute consultation where we will:

1. Review which articles of the Biotech Act most directly threaten your revenue, R&D pipeline, or supply chain.
2. Map your current EU advocacy assets (or lack thereof).
3. Outline a tailored influence plan for the Parliament and Council debates.

Do not wait for the final text to be published. By then, your competitors will have already shaped the rules in their favour.

Website contact form: hyperion-tree-digital.eu/contact/

Direct calendar link: calendly.com/harold-hyperion-tree-digital/30min

Let’s unlock your influence in Brussels.